Summary: Suvorexant, a dual orexin receptor antagonist commonly prescribed to help treat insomnia reduced levels of the Alzheimer’s-associated amyloid beta protein in the brain. The findings hint that the sleep medication could slow or stop Alzheimer’s disease, but researchers say more research is needed to confirm the viability of the approach. Source: WUSTL Sleep disturbances can be an early sign of Alzheimer’s disease. Many people eventually diagnosed with Alzheimer’s start experiencing difficulty falling and staying asleep years before cognitive problems such as memory loss and confusion emerge. It’s a vicious cycle: Alzheimer’s disease involves changes to the brain that disrupt...
